Workflow
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
BLFSBioLife Solutions(BLFS) ZACKS·2025-03-24 12:30

Core Viewpoint - The U.S. stock market showed slight gains on March 21, 2025, as investors reacted to the Federal Reserve's stable interest rate projections amidst concerns over President Trump's import tariffs [1] Group 1: Stock Market Overview - The majority of U.S. stock indices ended slightly positive, overcoming recent declines [1] - Investor sentiment remains cautious due to potential long-term economic impacts from enhanced import tariffs [1] - The Federal Reserve's unchanged interest rate cut projections contributed to a sense of economic stability [1] Group 2: Investment Strategy - Investors are encouraged to consider low-leverage stocks to mitigate risks during market volatility [2][6] - Recommended low-leverage stocks include BioLife Solutions (BLFS), Wildan Group (WLDN), Nextracker Inc. (NXT), Novo Nordisk (NVO), and EZCORP (EZPW) [2] - These stocks are characterized by low debt levels, making them safer options during economic downturns [2][5] Group 3: Understanding Leverage - Leverage refers to the practice of borrowing capital for operations and expansion, typically through debt financing [4] - Excessive debt financing can lead to significant losses, making low-leverage stocks preferable for risk-averse investors [5][6] - The debt-to-equity ratio is a common metric used to assess a company's financial risk, with lower ratios indicating better solvency [7] Group 4: Stock Selection Criteria - Stocks should have a debt-to-equity ratio lower than the industry median, a current price of at least 10,andanaverage20daytradingvolumeof50,000ormore[11]AdditionalcriteriaincludepositiveearningsgrowthexpectationsandastrongZacksRank[12]Group5:CompanyHighlightsBioLifeSolutions(BLFS):Reporteda3110, and an average 20-day trading volume of 50,000 or more [11] - Additional criteria include positive earnings growth expectations and a strong Zacks Rank [12] Group 5: Company Highlights - **BioLife Solutions (BLFS)**: Reported a 31% year-over-year revenue increase and a narrowing adjusted operating loss of 746 million [13][14] - Wildan Group (WLDN): Secured a 17.7millioncontract,withaprojectedearningsimprovementof13.217.7 million contract, with a projected earnings improvement of 13.2% year-over-year [15][16] - **Nextracker Inc. (NXT)**: Achieved a backlog of over 4.5 billion and a 7.3% year-over-year increase in adjusted earnings per share [17][18] - Novo Nordisk (NVO): Announced positive results from a phase 3 trial, with a long-term earnings growth rate of 24.2% [19][20] - EZCORP (EZPW): Reported a 14% year-over-year increase in adjusted net income and a 7% revenue growth [21]